|1.||Jaiswal, Anil K: 10 articles (02/2010 - 11/2002)|
|2.||Wu, Joseph M: 5 articles (03/2012 - 10/2004)|
|3.||Hsieh, Tze-chen: 4 articles (03/2012 - 10/2004)|
|4.||Knox, Richard: 4 articles (07/2010 - 11/2002)|
|5.||Iskander, Karim: 4 articles (03/2009 - 11/2002)|
|6.||Mittal, Balraj: 3 articles (12/2012 - 05/2011)|
|7.||Yu, Ke-Da: 3 articles (01/2012 - 07/2009)|
|8.||Shao, Zhi-Ming: 3 articles (01/2012 - 07/2009)|
|9.||Fan, Lei: 3 articles (01/2012 - 07/2009)|
|10.||Ross, David: 3 articles (08/2011 - 12/2008)|
05/30/2005 - "Interestingly, all the mice lacking expression of NQO1 and NQO2 protein demonstrated myelogenous hyperplasia of the bone marrow and increased granulocytes in the peripheral blood. "
11/29/2002 - "These results establish a role for NQO2 in protection against myelogenous hyperplasia and in metabolic activation of menadione, leading to hepatic toxicity. "
03/01/2009 - "NRH:quinone oxidoreductase 2 (NQO2) is known to protect against myelogenous hyperplasia. "
04/01/2006 - "Human NRH:quinone oxidoreductase 2 (NQO2) is a cytosolic protein that catalyzes the metabolic reduction of quinones and provides protection against myelogenous hyperplasia and chemical carcinogenesis. "
11/29/2002 - "Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity."
12/01/2008 - "These studies suggest that NQO1 and NQO2 are the principal enzymatic determinants of RH1 bioactivation in MDA468 tumor cells and that b5R, P450R, and XDH/XO are unlikely to play major roles. "
09/01/2004 - "Histologic analysis of the NQO2-/- mice tumors demonstrated proliferative activity. "
02/01/2002 - "To elucidate their role in carcinogenesis, the gene expression of human NQO1 and NQO2 in paired normal and tumor tissue samples was examined. "
12/01/2012 - "The present study did not find any significant association of NQO1 609C>T and NQO2 -3423G>A polymorphisms with susceptibility to EC or its clinical phenotypes (histopathology, tumor location or lymph node metastasis) or interactions with lifestyle risk factors (tobacco usage, smoking, alcohol habit and occupational exposures). "
01/01/2003 - "NQO2 activity is substantially raised in tumor samples from colorectal and hepatoma patients (up to 14-fold). "
|3.||Breast Neoplasms (Breast Cancer)
07/01/2009 - "In the first hospital-based study (n = 1604), we observed significant associations between the incidence of breast cancer and a 29 bp-insertion/deletion polymorphism (29 bp-I/D) and the rs2071002 (+237A>C) polymorphism, both of which are located within the NQO2 promoter region. "
01/15/2012 - "Our results suggest that NQO2, SOD2 and SOD3 may significantly modify prognosis of breast cancer patients and that their significance should be further characterized."
01/15/2012 - "Associations of transcript levels of oxidative stress-modifying genes SOD2, SOD3, NQO1 and NQO2 and their functional single nucleotide polymorphisms (SNPs) rs4880, rs1799895, rs2536512, rs699473, rs1800566 and rs1143684 with prognosis of breast cancer patients were studied. "
12/01/2009 - "Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2."
08/15/2009 - "We examined relationships between DFS and variants in NOS3, as well as NQO1, NQO2, and CBR3, among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial (S8897). "
|4.||Prostatic Neoplasms (Prostate Cancer)
12/01/2012 - "Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India."
10/22/2004 - "NQO2 was most abundant in CWR22Rv1, a model for prostate cancer transition from androgen-dependent to the hormone-refractory state, but was marginally expressed in JCA-1 cells as representing more advanced stage prostate cancer. "
06/01/2014 - "Specifically, we examined 71 single-nucleotide polymorphisms (SNP) in SULT2A1, SULT2B1, CYP1B1, COMT, CYP3A4, CYP3A5, CYP3A43, NQO1, and NQO2 and assessed the impact of the SNPs alone and in combination on prostate cancer progression and on circulating hormone levels. "
03/01/2012 - "In our continuing studies on the mechanism of prostate cancer prevention by resveratrol, focusing on the role of its recently discovered target protein, quinone reductase 2 (NQO2), we generated NQO2 knockdown CWR22Rv1 using short hairpin RNA (shRNA)-mediated gene silencing approach. "
|5.||Parkinson Disease (Parkinson's Disease)
10/15/2004 - "These studies also suggest that alterations in NQO2 activity might be an important factor in susceptibility to Parkinson's disease."
11/09/2001 - "We conducted a study of the potential association between idiopathic Parkinson's disease and polymorphisms of GSTM1, NQO1, and NQO2. "
02/01/2008 - "The results suggest that the association of the D promoter with Parkinson's disease may be due to an increase in expression of the NQO2 gene."
02/01/2008 - "Blood DNA from 80 control individuals and 118 age-matched Parkinson's disease patients were analyzed for NQO2 gene promoter polymorphisms. "
03/03/2005 - "No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes."
|3.||Vitamin K 3 (Menadione)
|5.||NAD(P)H Dehydrogenase (Quinone) (Quinone Reductase)
|6.||NRH - quinone oxidoreductase2
|8.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)